KBC Group NV Has $113,000 Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

KBC Group NV lifted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 40.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,336 shares of the company’s stock after acquiring an additional 385 shares during the period. KBC Group NV’s holdings in Axsome Therapeutics were worth $113,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. JPMorgan Chase & Co. grew its holdings in shares of Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after purchasing an additional 27,534 shares in the last quarter. PDT Partners LLC bought a new position in Axsome Therapeutics in the third quarter worth $1,052,000. Pallas Capital Advisors LLC acquired a new stake in Axsome Therapeutics during the fourth quarter worth $2,237,000. Captrust Financial Advisors bought a new stake in Axsome Therapeutics in the 3rd quarter valued at $514,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Axsome Therapeutics by 71.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company’s stock valued at $1,234,000 after buying an additional 5,737 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on AXSM shares. Robert W. Baird lifted their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price objective on shares of Axsome Therapeutics in a research note on Monday, January 13th. Mizuho increased their target price on Axsome Therapeutics from $122.00 to $137.00 and gave the stock an “outperform” rating in a report on Monday, February 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $139.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. Finally, StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $134.00.

Axsome Therapeutics Trading Down 3.4 %

Shares of NASDAQ AXSM opened at $105.76 on Friday. The company’s 50 day simple moving average is $94.57 and its 200 day simple moving average is $91.56. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $114.06. The firm has a market capitalization of $5.13 billion, a P/E ratio of -16.20 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same period last year, the company earned ($1.32) EPS. On average, analysts predict that Axsome Therapeutics, Inc. will post -4.72 EPS for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.